Last reviewed · How we verify

Celecoxib capsule

Xuhui Central Hospital, Shanghai · FDA-approved active Small molecule Quality 2/100

Celecoxib capsule is a Small molecule drug developed by Xuhui Central Hospital, Shanghai. It is currently FDA-approved.

Celecoxib capsule, marketed by Xuhui Central Hospital, Shanghai, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameCelecoxib capsule
SponsorXuhui Central Hospital, Shanghai
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Celecoxib capsule

What is Celecoxib capsule?

Celecoxib capsule is a Small molecule drug developed by Xuhui Central Hospital, Shanghai.

Who makes Celecoxib capsule?

Celecoxib capsule is developed and marketed by Xuhui Central Hospital, Shanghai (see full Xuhui Central Hospital, Shanghai pipeline at /company/xuhui-central-hospital-shanghai).

What development phase is Celecoxib capsule in?

Celecoxib capsule is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing